Associated Papers
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
39991480 (PubMed )
Supplement: mmc5.xlsx › Sheet1
Potential Opportunities for Pharmacogenetic-Based Therapeutic Exploitation of Xanthine Dehydrogenase in Cardiovascular Disease.
Massimo G et al.
Antioxidants (basel, Switzerland), 2024
Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine.
Zhou Y et al.
Science Advances, 2021
34516913 (PubMed )
Supplement: sciadv.abi6856_tables_s1_to_s8.zip › sciadv.abi6856_Table_S6.xlsx › Sheet1
Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: a population study.
Scheepers LE et al.
Journal of Hypertension, 2016
Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease.
Park SK et al.
Scandinavian Journal of Gastroenterology, 2016
Novel mutations in xanthine dehydrogenase/oxidase cause severe hypouricemia: biochemical and molecular genetic analysis in two Czech families with xanthinuria type I.
Stiburkova B et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2012
Genome-wide analysis to predict protein sequence variations that change phosphorylation sites or their corresponding kinases.
Ryu GM et al.
Nucleic Acids Research, 2009
19139070 (PubMed )
Supplement: gkn1008_nar-01723-s-2008-File011.xls › TypeI_
Associations of hypertension and its complications with variations in the xanthine dehydrogenase gene.
Yang J et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension, 2008
Functional characterization of human xanthine oxidase allelic variants.
Kudo M et al.
Pharmacogenetics and Genomics, 2008
Select a paper to view details